GNRH1 and ovarian hyperstimulation syndrome: In particular, GnRH agonists are generally proposed in women with BMI <25 kg/m2 (40), in poor responders (38, 41), and/or as a final trigger to minimize the ovarian hyperstimulation syndrome (OHSS) occurrence (42).